Drug Safety Update

The product information for all Glucagon-Like Peptide-1 (GLP-1) receptor agonists and dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor agonists has been further updated to highlight the potential risk o…

• Therapeutic area: Emergency medicine and 5 others
• Published: 29 January 2026

The Commission on Human Medicines (CHM) has endorsed changes to the risk minimisation measures for isotretinoin, following a review of the impact of the measures implemented in 2023. We ask healthcare professionals to review…

• Therapeutic area: Dermatology and 4 others
• Published: 22 January 2026

There is a risk of patient harm arising through medication error during a transition period where the original and new formulation of Rybelsus ® tablets, which have different stated mg doses but are bioequivalent, will both …

• Therapeutic area: Care home staff and 6 others
• Published: 17 December 2025

Idiopathic intracranial hypertension (IIH) has been very rarely reported in patients treated with mesalazine. Following a recent review, warnings for IIH are being added to the product information for all mesalazine products…

• Therapeutic area: Emergency medicine and 4 others
• Published: 4 December 2025

The Commission on Human Medicines (CHM) has endorsed changes to isotretinoin prescribing guidance. In addition, CHM is seeking further information from dermatology services who prescribe isotretinoin to inform any future cha…

• Therapeutic area: Dermatology and 4 others
• Published: 27 October 2025

The annual #MedSafetyWeek campaign takes place from 3 to 9 November 2025. This year’s campaign theme is ‘we can all help make medicines safer.’

• Therapeutic area: Anaesthesia and intensive care and 39 others
• Published: 23 October 2025

Patients should be reminded and reassured that there is no evidence that taking paracetamol during pregnancy causes autism in children. Paracetamol is recommended as the first-choice pain reliever for pregnant women, used at…

• Therapeutic area: Anaesthesia and intensive care and 34 others
• Published: 23 September 2025

Updated safety and educational materials are now available to support the implementation of the regulatory measures announced in the November 2023 National Patient Safety Alert and the September 2024 Drug Safety Update. They…

• Therapeutic area: General practice and 5 others
• Published: 10 June 2025

Psychological side effects such as anxiety, low mood, sleep disturbance, poor concentration, and forgetfulness have been infrequently reported in people with cystic fibrosis treated with Kaftrio. Healthcare professionals sho…

• Therapeutic area: General practice and 2 others
• Published: 7 May 2025

Healthcare professionals and patients are reminded of the risk of severe asthma attacks and increased mortality associated with overuse of SABA with or without anti-inflammatory maintenance therapy in patients with asthma. H…

• Therapeutic area: General practice and 2 others
• Published: 24 April 2025